NCT03836482View on ClinicalTrials.gov

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2027

Conditions
Acute on Chronic Systolic Congestive Heart FailureCardiorenal Syndrome
Interventions
DEVICE

Selective Cytopheretic Device

Treatment will be delivered for 4 hours a day for up to 6 consecutive days.

Sponsors

Lead Sponsor

SeaStar Medical
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

University of Michigan

OTHER

collaborator

Innovative BioTherapies (IBT)

INDUSTRY

lead

SeaStar Medical

INDUSTRY

NCT03836482 - Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD | Biotech Hunter | Biotech Hunter